173 related articles for article (PubMed ID: 12821477)
1. Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects.
Gajjar DA; Bello A; Ge Z; Christopher L; Grasela DM
Antimicrob Agents Chemother; 2003 Jul; 47(7):2256-63. PubMed ID: 12821477
[TBL] [Abstract][Full Text] [Related]
2. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
[TBL] [Abstract][Full Text] [Related]
3. Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats.
Kastner M; Rahm U; Baumann-Wilschke I; Bello A; Stahlmann R
Arch Toxicol; 2004 Feb; 78(2):61-7. PubMed ID: 14661070
[TBL] [Abstract][Full Text] [Related]
4. Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.
Kansagra KA; Parmar D; Jani RH; Srinivas NR; Lickliter J; Patel HV; Parikh DP; Heading H; Patel HB; Gupta RJ; Shah CY; Patel MR; Dholakia VN; Sukhadiya R; Jain MR; Parmar KV; Barot K
Clin Pharmacokinet; 2018 Jan; 57(1):87-102. PubMed ID: 28508936
[TBL] [Abstract][Full Text] [Related]
5. Nasogastric administration of garenoxacin as crushed tablets with and without concomitant enteral feeding in healthy subjects.
Krishna G; Noveck R; Vargas R; Grasela D; Wang Z
Drugs R D; 2007; 8(1):43-50. PubMed ID: 17249848
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
Wang Z; Grasela DM; Krishna G
Clin Ther; 2007 Jun; 29(6):1098-106. PubMed ID: 17692724
[TBL] [Abstract][Full Text] [Related]
8. Effect of garenoxacin on eubacteria in the normal intestinal microflora when administered concomitantly with digoxin.
Nord CE; Meurling L; Russo RL; Bello A; Grasela DM; Gajjar DA
J Chemother; 2003 Jun; 15(3):244-7. PubMed ID: 12868550
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
10. Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
Chung DT; Tsai CY; Chen SJ; Chang LW; King CH; Hsu CH; Chiu KM; Tan HC; Chang YT; Hsu MC
Antimicrob Agents Chemother; 2010 Jan; 54(1):411-7. PubMed ID: 19884374
[TBL] [Abstract][Full Text] [Related]
11. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects.
Stass H; Dalhoff A; Kubitza D; Schühly U
Antimicrob Agents Chemother; 1998 Aug; 42(8):2060-5. PubMed ID: 9687407
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM
Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability and pharmacokinetics of the new long-acting quinolone DW-116 after single and multiple dosing in healthy subjects.
Meyerhoff C; Dilger C; Yoon SJ; Chung YH; Lee DK; Lee CW; Ryu JM; Choi MS; Pabst G; Reh C
J Antimicrob Chemother; 1998 Sep; 42(3):349-61. PubMed ID: 9786475
[TBL] [Abstract][Full Text] [Related]
15. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry.
Liu MY; Meng SN; Wu HZ; Wang S; Wei MJ
Clin Ther; 2008 Apr; 30(4):641-53. PubMed ID: 18498913
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
18. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
19. Multiple-dose pharmacokinetics of lomefloxacin: rationale for once-a-day dosing.
Mant TG
Am J Med; 1992 Apr; 92(4A):26S-32S. PubMed ID: 1316066
[TBL] [Abstract][Full Text] [Related]
20. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.
Chien SC; Wong FA; Fowler CL; Callery-D'Amico SV; Williams RR; Nayak R; Chow AT
Antimicrob Agents Chemother; 1998 Apr; 42(4):885-8. PubMed ID: 9559801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
